ClinicalTrials.gg
RecruitingNCT06755814ARGONAUTUpdated Nov 18, 2025

ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)

An observational study in Community Acquired Pneumonia (CAP), sponsored by Societa Italiana di Pneumologia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Societa Italiana di Pneumologia · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,298
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Community-Acquired Pneumonia with a site in Italy — 6 open to participants now, 6 under way, 2 of them phase 3. Community-Acquired Pneumonia · Italy.

Planned enrollment
4th of 11
1,298 · median 500
Started
2025
with 2 others
Observational
11 of 17
4 open now
Registered
14th of 17
by date
Lead sponsor
1 of 17
Societa Italiana di Pneumologia

Among the 17 studies in Community-Acquired Pneumonia with a site in Italy, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2025, is one of 11 observational ones, and was the 14th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

6 of the 17 studies in Community-Acquired Pneumonia with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Community-Acquired Pneumonia with a site in Italy, or all of them as a file.
02

Study summary

This multicentric, prospective study aims at:

evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical, microbiological and genetic analysis on collected samples.

Read the detailed description

Primary endpoint:

Collection of in- hospitalisation mortality for all causes in immunocompromised patients with CAP enrolled.

Secondary endpoints:

Collection of data on admission and during hospitalisation to evaluate clinical response to empirical treatments (including antibiotic therapy) related to severity of disease and microbiological etiology.

Prevalence of cardiovascular events and all-cause mortality during hospitalization or after discharge.

Biochemical, microbiological and genetic analysis on collected samples.

03

Conditions studied

  • Community Acquired Pneumonia (CAP)

Keywords

  • CAP
  • Immunosuppressed
  • Immunocompromised
  • Pneumonia
  • community-acquired pneumonia;
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Immunosuppressed patients with Community-Acquired Pneumonia will be enrolled during hospitalization in Italian Pneumology, Infectious Diseases and Emergency Departments selected on their specific experteeze and know-how. Upon discharge, patients will be followed up at 30 days, 3 months, 6 months and 12 months after discharge.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Hospitalized patients with a confirmed diagnosis of Community-Acquired Pneumonia (CAP) characterized by at least one of the following risk factors for :

  • AIDS,
  • Aplastic anemia;
  • Asplenia;
  • Hematologic (e.g., lymphoma/acute or chronic myeloid leukemia/multiple myeloma);
  • Chemotherapy within the last 3 months;
  • Neutropenia defined as a white blood cell count less than 500/dL on a complete blood count;
  • Use of biologics (including trastuzumab and therapy for diseases (e.g., anti-TNF α), prescribed within the last 6 months before hospital admission;
  • Solid organ transplant;
  • Bone marrow transplant;
  • Chronic oral use (>10 mg/day prednisone or equivalent ≥3 months before accessing the ED, or cumulative dose > 600 mg prednisone);
  • Use of corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent ≥14 days or cumulative dose > 600 mg prednisone;
  • Active malignancy;
  • Malignancy within one year of pneumonia (excluding patients with localized skin cancer or early-stage malignancy);
  • Lung malignancy with neutropenia/chemotherapy;
  • Other solid malignancy with neutropenia/chemotherapy;
  • Other immunodeficiency (including congenital/genetic immunosuppression and immunosuppressive therapy secondary to hematologic malignancy or solid malignancy);
  • Primary immunodeficiency.

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,298 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. In-hospital mortality for all causes in immunocompromised patients with CAP enrolled in the study.

    Recording in-hospital mortality for all causes in immunocompromised patients with CAP enrolled in the study.

    Time frame: During hospitalization corresponding to study enrollment (1 day to 2 weeks of hospitalization on average)

Secondary outcomes

  1. Time to clinical stability

    Time to clinical stability calculated as the number of days from the date of admission to the date that the patient meets clinical stability criteria, up to 8 days. Clinical stability is defined as follows: improved clinical signs (improved cough and shortness of breath), lack of fever for at least 8 hours, improving leukocytosis (decreased at least 10% from the previous day), and tolerating oral intake.

    Time frame: DAY 1 to 8

  2. Mortality for all causes in immunocompromised patients with CAP

    Mortality for all causes in immunocompromised patients with CAP enrolled in the study.

    Time frame: 30 days, 3 months, 6 months and 12 months after hospital discharge.

  3. New hospitalizations in immunocompromised patients with CAP.

    Recording new hospitalizations in immunocompromised patients with CAP enrolled in the study.

    Time frame: 30 days, 3 months, 6 months and 12 months after hospital discharge.

  4. Prevalence of cardiovascular events in immunocompromised patients with CAP.

    Prevalence of cardiovascular events in immunocompromised patients with CAP enrolled in the study.

    Time frame: 30 days, 3 months, 6 months and 12 months after hospital discharge.

  5. Length of hospital stay (days)

    Time frame: Through hospital discharge, ranging from 1 day to 2 weeks

  6. ICU admission %

    Time frame: During hospitalization corresponding to study enrollment (1 day to 2 weeks of hospitalization on average)

  7. Need for mechanical ventilation %

    Time frame: During hospitalization (1 day to 2 weeks on average)

  8. Lenght of mechanical ventilation (Hours)

    Time frame: During hospitalization (1 day to 2 weeks on average)

  9. Rate of antibiotic therapy modification (%)

    Time frame: During hospitalization (1 day to 2 weeks on average)

  10. Subsequent re-admission within 1 year

    Time frame: Within 365 days after hospital discharge

  11. Characterization of Microbiological Etiology Using 16S rRNA Sequencing and Whole-Genome Sequencing

    Microbiological analysis will be performed on sputum, bronchoalveolar lavage (BAL), and bronchial aspirate (BAS) samples. The 16S rRNA sequencing will be conducted to evaluate the relative abundance of identified bacterial genera (percentage/total) and to calculate alpha diversity indices, including Shannon and Equitability indices. For samples where bacterial strains are isolated, whole-genome sequencing (WGS) will be performed to identify and study resistance, virulence, and pathogenicity genes. These findings will be correlated with clinical data to provide insights into microbiological etiology. Data will be summarized as relative abundances, diversity indices, and the presence/absence of key genomic features.

    Time frame: Through study completion, for up to 4 years

07

Study locations

1 of 1 sites recruiting
  • Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano Via Francesco Sforza 35 20122 Milan Italy
    Milan, Milano 20122, Italy
    Recruiting
08

References and documents

Publications

  • Garcia-Vidal C, Fernandez-Sabe N, Carratala J, Diaz V, Verdaguer R, Dorca J, Manresa F, Gudiol F. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J. 2008 Sep;32(3):733-9. doi: 10.1183/09031936.00128107. Epub 2008 May 28. PubMed 18508820 ↗
  • Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST. PubMed 31573350 ↗
  • Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, Pesci A, Blasi F, Torres A. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax. 2013 Nov;68(11):997-9. doi: 10.1136/thoraxjnl-2013-203384. Epub 2013 Jun 17. PubMed 23774884 ↗
  • Evans SE, Ost DE. Pneumonia in the neutropenic cancer patient. Curr Opin Pulm Med. 2015 May;21(3):260-71. doi: 10.1097/MCP.0000000000000156. PubMed 25784246 ↗
  • Feldman C. Pneumonia associated with HIV infection. Curr Opin Infect Dis. 2005 Apr;18(2):165-70. doi: 10.1097/01.qco.0000160907.79437.5a. PubMed 15735422 ↗
  • Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S, Reyes LF, Rupp J, Gonzalez Del Castillo J, Blasi F, Aliberti S, Restrepo MI; GLIMP Investigators. Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clin Infect Dis. 2019 Apr 24;68(9):1482-1493. doi: 10.1093/cid/ciy723. PubMed 31222287 ↗
  • Carugati M, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, Encheva M, Gallego M, Leuschner P, Ruiz-Buitrago S, Battaglia S, Fantini R, Pascual-Guardia S, Marin-Corral J, Restrepo MI; GLIMP Collaborators. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. Eur J Clin Microbiol Infect Dis. 2020 Aug;39(8):1513-1525. doi: 10.1007/s10096-020-03870-3. Epub 2020 Apr 3. PubMed 32242314 ↗
  • Ramirez JA, Musher DM, Evans SE, Dela Cruz C, Crothers KA, Hage CA, Aliberti S, Anzueto A, Arancibia F, Arnold F, Azoulay E, Blasi F, Bordon J, Burdette S, Cao B, Cavallazzi R, Chalmers J, Charles P, Chastre J, Claessens YE, Dean N, Duval X, Fartoukh M, Feldman C, File T, Froes F, Furmanek S, Gnoni M, Lopardo G, Luna C, Maruyama T, Menendez R, Metersky M, Mildvan D, Mortensen E, Niederman MS, Pletz M, Rello J, Restrepo MI, Shindo Y, Torres A, Waterer G, Webb B, Welte T, Witzenrath M, Wunderink R. Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. Chest. 2020 Nov;158(5):1896-1911. doi: 10.1016/j.chest.2020.05.598. Epub 2020 Jun 16. PubMed 32561442 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.

Of 38 observational studies under Community-Acquired Pneumonia, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's planned 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Jan 1, 2025
StartActual
Aug 11, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06755814
Lead sponsor
Societa Italiana di Pneumologia
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Aug 11, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 18, 2025

Study contacts

Francesco B.A. Blasi, MD,
Contact
francesco.blasi@unimi.it
0250320627 ext. +39
Concetta Sirena, Phd
Contact
ricerche@sipirs.it
342 0790871 ext. +39
Francesco B.A. Blasi, MD
study chair · Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion